Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Benoît Bédat, Jérôme Plojoux, Jade Noel, Anna Morel, Jonathan Worley, Frédéric Triponez, Wolfram Karenovics. Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019

Member's Comments

No comment yet.

Related content which might interest you: The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021 Year: 2022 Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space? Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013 A clinical comparison of intrapleural heparin versus urokinase in the management of tuberculous pleurisy Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005 Intrapleural use of dornase alfa and tissue plasminogen activator are successful as treatment in pediatric empyema: a pilot study Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes Year: 2018 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019 Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020 Year: 2020 Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Variable adoption of intrapleural fibrinolytic therapy for pleural space infections Source: International Congress 2018 – Pleural interventions Year: 2018 Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Intrapleural urokinase in the management of empyema in children Source: Eur Respir J 2004; 24: Suppl. 48, 620s Year: 2004 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018